ODYSSEAN INVESTMENT TRUST PLC

1. ODYSSEAN INVESTMENT TRUST PLC 2018-02-05 → present
2. ODYSSEAN SMALLER COMPANIES OPPORTUNITIES PLC 2018-01-09 → 2018-02-05
3. ODYSSEAN SMALLER COMPANY OPPORTUNITIES PLC 2017-12-21 → 2018-01-09

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Accounting basis

IFRS

Reporting scope

Standalone (parent only)

Auditor

KPMG LLP

Audit opinion

Unaudited (audit-exempt)

Going concern

Affirmed

“The Directors believe, having considered the Company's investment objectives, risk management policies, capital management policies and procedures, nature of the portfolio and expenditure projections, that the Company has adequate resources, an appropriate financial structure and suitable management arrangements in place to continue in operational existence for the foreseeable future and, more specifically, that there are no material uncertainties relating to the Company that would prevent its ability to continue in such operational existence for at least twelve months from the date of the approval of this Half Year Report.”

Significant events

• “Market turmoil in anticipation of "Liberation Day" where the President of the USA laid out his plans for import-related tariffs on goods flowing to the USA.”
• “Dialight's shares rose c.98% through the period with performance ahead of expectations and progress on operational improvement (cost saving projects, SKU reductions, improved pricing and inventory reduction).”
• “Elementis disposed of its Talc division for c.$121m and returned c$50m to shareholders via a share buyback.”
• “Auction Technology Group (ATG) announced a highly priced acquisition while downgrading its outlook for full year margins driven by product mix.”
• “NCC Group confirmed it was looking at options for its Escode division including a potential sale and also conducting a review of its Cyber business.”
• “Genus received FDA approval for its new, disease resistant pig line and announced the sale of interest in its China subsidiary to create a JV.”
• “Spire Healthcare commenced a process to look at strategic options to maximise shareholder value including a possible sale of the company.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

20

last 12 months

Capital events

15

last 24 months

Officers appointed

1

last 12 months

Officers resigned

1

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.